# Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis

> **NCT07565103** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Senju USA, Inc.** · enrollment: 426 (estimated)

## Conditions studied

- Bacterial Conjunctivitis

## Interventions

- **DRUG:** SUM-191
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07565103
- **Lead sponsor:** Senju USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-08-15
- **Final completion:** 2028-08-15
- **Target enrollment:** 426 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07565103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07565103, "Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07565103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*